Two independent preclinical advances aim to expand CAR‑T impact in solid tumors. One study reported that knocking out dual prostaglandin E2 (PGE2) receptors in engineered T cells neutralizes an immunosuppressive pathway and boosts anti‑tumor activity in solid‑tumor models. Separately, Columbia University researchers described HLA‑independent T (HIT) receptors—ultra‑sensitive CAR‑like constructs that detected low CD70 expression and eradicated diverse solid tumor models in animals. Both approaches attack key barriers—tumor immunosuppression and low antigen density—using genetic engineering to augment cell potency and selectivity. Sponsors and cell‑therapy developers will watch for translational work and safety profiling ahead of clinical translation.